Clinical trials: Resectable Lung Non-Small Cell Carcinoma
Lung Neoplasm Malignant, Resectable Lung Non-Small Cell Carcinoma
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
The objective of this study is to evaluate the performances of the Six-Minute Stepper Test (6MST) and Sit To Stand test (STST) to predict post-operative complications after minimally invasive lung cancer resection.
- Trial name
- PREOTEST (NCT03824977)
- Testing
- Six minutes stepper test (6MST), Sit to stand test (STST)
- Where
- France
- Volunteers
- 122 people
- Sponsor
- University Hospital, Rouen
Lung Cancer, Metastatic Cancer
Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00601848
- Testing
- chemotherapy, porfimer sodium, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-small Cell Lung Cancer
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
In this single-arm, phase II clinical trial, patients with resectable, EGFR-mutated, stage II-IIIB NSCLC received neoadjuvant therapy with furmonertinib (oral, 80 mg once daily, stopped 1 week preoperatively) in combination with…
- Trial name
- NCT05430802
- Testing
- Furmonertinib+cisplating/pemetrexed
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
EGF-R Positive Non-Small Cell Lung Cancer
The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients.
- Trial name
- NCT06287593
- Testing
- ctDNA monitoring
- Volunteers
- 300 people
- Sponsor
- Zhejiang University
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally…
- Trial name
- NCT04832854
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Adebrelimab
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.
- Conditions
- Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
- Trial name
- NCT07031154
- Testing
- Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Fusion of anaplastic lymphoma kinase (ALK) is an important driving gene for NSCLC, with an incidence rate of 3-7%. In patients with advanced ALK mutation NSCLC, first-line use of ALK inhibitors significantly improves progression…
- Trial name
- NCT06282536
- Testing
- Iruplinalkib, surgery
- Volunteers
- 20 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Stage IIIA Non-Small Cell Lung Cancer
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemoradiotherapy, the usual approach to non-small cell lung cancer, in combination with pembrolizumab (MK-3745), followed by…
- Trial name
- NCT02987998
- Testing
- Cisplatin, Etoposide, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Nathan Pennell, MD, PhD
Non Small Cell Lung Cancer
Evaluation of Preoperative Endobronchial Ultrasound (EBUS) in Non Small Cell Lung Cancer (NSCLC)
This study aims to assess both the role and cost-effectiveness of EBUS in preoperative Non small cell lung cancer staging. This controlled multicentric study will be conducted in 22 centers in France.
- Trial name
- EVIEPEB (NCT00960271)
- Testing
- EBUS
- Where
- France
- Volunteers
- 363 people
- Sponsor
- University Hospital, Rouen
Non Squamous Non Small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential…
- Trial name
- NCT05962021
- Testing
- Toripalimab plus Chemotherapy
- Volunteers
- 126 people
- Sponsor
- Peking University People's Hospital
Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
This phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC).
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- N-PLANC (NCT06918132)
- Testing
- Biospecimen Collection, Cemiplimab, Fianlimab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Non-small Cell Lung Cancer
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Despite aggressive surgery and chemotherapy, the risk of lung cancer recurrence remains high in most patients. This study aims to determine if a novel immune therapy consisting of two drugs is feasible and potentially increases…
- Trial name
- NCT03130764
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- Columbia University
Non-Small Cell Lung Cancer, Anti Angiogenesis
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery…
- Trial name
- NCT06475755
- Testing
- Immunochemotherapy combined with antiangiogenic, Immunochemotherapy
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Tang-Du Hospital
NSCLC (Non-small Cell Lung Cancer)
Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC
This is a prospective, open, single-center, single-arm phase II clinical study in non-small cell lung cancer (NSCLC) without common EGFR-sensitive mutations (Ex19del and L858R) or ALK fusion variants identified in the central…
- Trial name
- TianjinCIH (NCT07438600)
- Testing
- Sacituzumab Govitecan (SG)+Toripalimab
- Volunteers
- 38 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC, Non Small Cell Lung Cancer
Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer
The purpose of this study is to study the clinical and biologic effects of Tumor Treatment Fields (TTFields) in patients undergoing resection of stage I-IIIA Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT06552000
- Testing
- NovoTTF-200T System
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Non-Small Cell Lung Cancer
Prevention of Tumor Spread Due to Lung Cancer Surgery
This study will investigate operative techniques to reduce the risk of tumor spread as a result of lung cancer surgery. Recent studies indicate that tumor cells may be released into the bloodstream due to handling of the lung…
- Trial name
- NCT00341380
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
NSCLC, NSCLC (Non-small Cell Lung Cancer)
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
The primary objective of this study is to evaluate whether neoadjuvant SBRT as an immunomodulator in combination with apalolimab and toripalimab (QL1706) plus chemotherapy improves the pathological complete response (pCR) rate in…
- Trial name
- NCT07286942
- Testing
- apalolimab and toripalimab (QL1706)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer
Mechanism of Action Trial of ColoAd1
To assess the pattern of ColoAd1 viral delivery and viral expression within colon tumour tissue when administered by intra-tumoural injection or within colon, non-small cell lung, bladder and renal cell tumour tissues following…
- Conditions
- Resectable Colon Cancer, Resectable Non-small Cell Lung Cancer, Resectable Bladder Cancer, Resectable Renal Cell Carcinoma
- Trial name
- MOA (NCT02053220)
- Testing
- Colo-Ad1
- Where
- 2 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Akamis Bio
Lung Cancer Stage II, PD-1 Antibody
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic…
- Conditions
- Lung Cancer Stage II, PD-1 Antibody, Non-small Cell Lung Cancer
- Trial name
- NCT04108013
- Testing
- SHR-1210, Carboplatin and Paclitaxel-albumin
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing